Fall 🍂 is in the air: latest news on AI drug discovery

Too much of it kills you." A new report by Data Bridge Market Research analyses the global Artificial Intelligence (AI) in drug discovery market and forecasts that is expected to reach the value of USD 24,618.25 million by 2029, at a CAGR of 53.3% during the forecast period. The start of the world's first Phase 1 clinical trial of a drug developed from scratch using AI was announced by Insilico Medicine. "At the core of this issue is the complexity of human biology. After decades of molecular biology research, we're lucky if we know 5% of the circuitry of human disease." Just to give you a perspective, this is just the 5% of a simplified view of the brain's circuitry (for more about AI neuroscience news): Owkin's CEO Dr. T Clozel (his parents were the founders of Switzerland's Actelion), is intent on using AI to usher in a new era of drug development, by accessing data at scale with federated learning to preserve patient privacy and data security, and by creating an interpretable AI to answer a broad range of research questions. Last September rapid diagnostic solutions for breast and colorectal cancer from Owkin have been granted approval for use, while this month Sanofi's chief dealmaker (Alban de La Sablière) heads to Owkin as CBO, and all these after Owkin secured $80 million from Bristol Myers Squibb last year and a total raised to over $300 million. The Chicago-based Tempus (@TempusLabs), that specialises in AI and precision medicine and has one of the world's largest libraries of clinical and molecular data, announced this week it raised $275 million through equity from previous investors and debt financing from Ares Management (so far the company has raised over $1.3 billion). And also this month GSK announced that expanded its collaboration with Tempus to improve clinical trial design, speed up enrolment and identify drug targets. "This collaboration will provide GSK with unique insights to discover better medicines and transform drug discovery.